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Objectives: To evaluate (1) changes in clinical, biochemical and echocardiographic parameters, (2) whether
deterioration in exercise capacity and resting oxygen saturation (SatO2-rest) are related with adverse outcome
and (3) its additional value in predicting outcome in Eisenmenger patients.
Methods: Seventy-seven (36±14 years, 30% male) patients were included and prospectively followed. Changes
between baseline and ﬁnal visit were evaluated. Clinical deterioration was deﬁned as a deterioration in exercise
capacity or SatO2-rest. Univariate and multivariate analyses were performed to evaluate predictors of outcome
deﬁned as the need for hospitalization due to right heart failure, transplantation, or all-cause mortality. Finally,
the additional prognostic value of deterioration in exercise capacity and SatO2-rest was evaluated.
Results:During amean follow-up period of 4.0±2.1 years, 27 (35%) events occurred. Patients in the event-group
presented with an deterioration in NYHA class (Pb0.0001), 6 minute walk distance (P=0.006) and SatO2-rest
(Pb0.0001). After adjustment for baseline variables, multivariate Cox regression analysis indicated that clinical
deterioration was independently associated with adverse outcome.
Conclusions: Clinical deterioration, deﬁned as a deterioration in exercise capacity or SatO2-restwas associatedwith
adverse outcome in Eisenmenger patients. Moreover, these parameters provided additional information onwhich
patients would develop an event and may beneﬁt from initiation or escalation of disease targeting therapy.© 2012 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Approximately 5–10% of patients with congenital heart disease
develop pulmonary arterial hypertension of variable severity [1].
Eisenmenger syndrome, as ﬁrst described by Dr. Paul Wood, repre-
sents a pathophysiological condition of pulmonary arterial hyperten-
sion associated with shunt reversal [2,3]. Several variables have been
related with poor prognosis in this patient population, including
complex congenital heart defect, higher New York Heart Association
(NYHA) class, renal dysfunction, signs of right heart failure, a history
of arrhythmias, iron depletion, and elevated brain natriuretic pep-
tides [4–10]. Although Eisenmenger patients have lower annual mor-
tality rates and a better prognosis when compared to patients with
idiopathic pulmonary arterial hypertension, their life expectancy remainsardiology, University Hospitals
16 344369; fax:+32 16 344240.
. Budts).
Ltd. All rights reserved.signiﬁcantly reduced [5,6,8,11,12] and there is evidence of progression of
pulmonary vascular disease over a time period as short as 16 weeks [13].
Disease targeting therapies have shown to increase exercise capacity and
even improve survival in Eisenmenger patients [14].
According to the current pulmonary hypertension guidelines the need
for starting or escalating disease targeting therapy in these patients
requires knowledge of variables reﬂecting disease severity at a certain
time point as well as variables reﬂecting disease progression and their
relationship with clinical outcome. A practical table, including parame-
terswith established importance in pulmonary hypertension, is included
in the practice guidelines and deﬁnes treatment goals for these patients
[15]. However, most of these target values are based on studies evaluat-
ing patients with idiopathic pulmonary arterial hypertension.
Therefore, this study aimed at evaluating (1) changes in clinical,
biochemical and echocardiographic parameters during follow-up,
(2) changes in exercise capacity and resting oxygen saturation
(SatO2-rest) and their relation with adverse outcome and (3) the
additional value of a deterioration in exercise capacity or in SatO2-rest
in predicting adverse outcome in Eisenmenger patients.
it.
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2.1. Patient selection
Table 1
Characteristics of patients presenting with or without an event at baseline and ﬁnal visBaseline Final visit
No-event group, N=50 Event group, N=27 P-value No-event group, N=50 Event group, N=27 P-value
Age (years) 33±12 40±16 0.031 37±11⁎ 43±16⁎ 0.125
Male gender, n (%) 17 (34) 6 (22) 0.281 17 (34) 6 (22) 0.281
Down, n (%) 29 (58) 9 (33) 0.039 29 (58) 9 (33) 0.039
Diagnosis (%)
ASD/VSD/AVSD/PDA/Other
6/32/36/8
18
26/22/19/7
26
– 6/32/36/8
18
26/22/19/7
26
–
Follow-up time (years) 4.4±2.0 3.3±2.3 0.034 4.4±2.0 3.3±2.3 0.034
Medication
DTT (%)
No/Mono/Double/Triple
76/24/0/0 52/33/15/0 72/20/4/4 26/48/11/15
ERA, n (%) 11 (22) 12 (44) 0.040 14 (29) 17 (63) 0.004
PDE-5, n (%) 1 (2) 4 (15) 0.029 4 (8) 6 (22) 0.089
Prostacyclin, n (%) 0 (0) 1 (4) 0.171 2 (4) 3 (11) 0.247
Diuretics, n (%) 9 (18) 10 (37) 0.064 9 (18) 14 (52) 0.004
ACE-inhibitor/Sartan, n (%) 4 (8) 5 (19) 0.160 3 (6) 5 (18) 0.113
Beta-blocker, n (%) 3 (6) 3 (12) 0.396 5 (10) 3 (11) 0.975
Calcium antagonist, n (%) 2 (4) 2 (7) 0.494 0 (0) 2 (7) 0.061
Digoxin, n (%) 7 (14) 6 (22) 0.338 8 (16) 7 (26) 0.384
Antiplatelet drugs, n (%) 5 (10) 4 (15) 0.530 2 (4) 3 (11) 0.269
Anticoagulation, n (%) 5 (10) 10 (37) 0.004 5 (10) 12 (44) 0.001
Allopurinol, n (%) 11 (22) 7 (22) 0.666 16 (32) 11 (41) 0.611
Oxygen, n (%) 1 (2) 5 (19) 0.021 2 (4) 3 (11) 0.269
Phlebotomy, n (%) 8 (16) 10 (37) 0.037 9 (18) 7 (25) 0.558
Clinical parameters
NYHA, n (1–4) 2/33/15/0 2/9/15/1 0.040 7/25/12/0 0/4/17/6⁎ b0.0001
NYHA ≥3, n (%) 15 (30) 16 (59) 0.012 12 (24) 23 (85)⁎ b0.0001
6MWD (m) 398±117 334±119 0.101 413±111 254±137⁎ 0.001
6MWDb300 m, n (%) 4 (8) 11 (41) 0.125 3 (7) 16 (59)⁎ 0.002
BMI (kg/m2) 25±5 26±5 0.522 25±4 25±6 0.912
Syst BP (mm Hg) 114±14 125±21 0.006 112±14 113±28 0.839
Diast BP (mm Hg) 70±10 77±14 0.010 67±6 70±13 0.339
SatO2-rest (%) 84±7 84±7 0.807 84±7 78±9⁎ 0.014
Biochemical parameters
Hematocrit (%) 59±6 57±9 0.342 59±8 55±10 0.112
Hemoglobin (g/dL) 19.8±2.0 18.9±2.7 0.108 19.9±2.6 17.8±3.8 0.011
MCV (fL) 94±8 89±9 0.031 95±7 88±10 0.006
MCH (pg) 32±3 29±4 0.002 32±3⁎ 29±4⁎ 0.004
Platelets (×109/L) 161±54 168±67 0.648 141±53 159±66 0.234
Creatinine (mg/dL) 1.02±0.20 1.16±0.41 0.112 0.94±0.21 1.10±0.34 0.041
Uric acid (mg/dL) 6.5±1.9 7.5±2.6 0.077 6.0±2.0 7.0±3.0 0.226
Iron deﬁciency, n (%) 11 (22) 15 (56) 0.002 10 (20) 12 (44) 0.011
Echocardiographic parameters
LA apical (mm) 43±9 49±10 0.008 43±10 50±10 0.007
RA apical (mm) 45±8 52±10 0.001 46±10 53±12 0.023
LV apical (mm) 39±10 37±8 0.452 38±8 36±6 0.190
RV apical (mm) 36±10 43±10 0.003 35±11 46±14⁎ 0.001
LV EF (%) 64±9 65±1 0.585 66±10 62±13 0.217
RV function 1.4±0.6 2.2±0.8 b0.0001 1.4±0.6 2.5±1.0 b0.0001
TAPSE (mm) 18.5±4.0 16.0±4.1 0.024 20.3±4.8 15.1±3.9⁎ b0.0001
sPAP (mm Hg) 82±24 86±26 0.552 80±17 85±16 0.357
ASD: atrial septal defect; VSD: ventricular septal defect; AVSD: atrioventricular septal defect; PDA: patent ductus arteriosus; DTT: disease targeting therapy; ERA: endothelin
receptor antagonist; PDE5: phosphodiesterase 5 inhibitor; NYHA: New York Heart Association; 6MWD: 6 minute walk distance: BMI: body mass index; SatO2-rest: resting oxygen
saturation; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin; LA: left atrium; RA: right atrium; LV: left ventricle; RV: right ventricle; TAPSE: tricuspid annular
plane systolic excursion.
⁎ Pb0.005 change from baseline to ﬁnal visit.Patients with Eisenmenger physiology were recruited from the Belgian Eisenmenger
registry, previously described [16]. Patients were prospectively followed in each centre
with scheduled consultations, irrespective of clinical status. The study protocol conformed
to theDeclarationofHelsinki and the Institutional ReviewBoardof eachparticipating centre
approved the registry and all patients gave written informed consent before inclusion. The
authors of this manuscript have certiﬁed that they comply with the Principles of Ethical
Publishing in the International Journal of Cardiology.
2.2. Data collection at baseline
Demographic data,medical history (type of congenital heart defect, Down syndrome or
not, surgical procedures, and non-cardiac history), clinical characteristics (NYHA class,
blood pressure, body mass index, SatO2-rest, 6 minute walk distance), biochemical data(hematocrit, hemoglobin, mean corpuscular volume, mean corpuscular hemoglobin, iron
status, creatinine, uric acid), technical investigations (transthoracic echocardiography)and treatment were collected. Complex anatomywas deﬁned as atrioventricular septal de-
fect, transposition of the great arteries, truncus arteriosus and univentricular hearts.
NYHA classiﬁcation was based on the 1994 revisions to the classiﬁcation of functional
capacity and objective assessment of patients with diseases of the heart [17]. Oxygen
saturation was measured after 5 minutes of sitting on a bench with a transcutaneous
oximeter placed on one of the ﬁngers. In patients with patent ductus arteriosus, it was
measured on the left hand. Iron deﬁciency was deﬁned as ferritin b30 ng/mL or ferritine
30–100 ng/mL and a transferrin saturation b20% [6]. Standard 2D gray-scale and Doppler
examinations were performed. Left ventricular function was assessed from parasternal
two-dimensional M-mode measurements using Teichholz formula. In the apical 4-chamber
view, the superior-inferior dimensions of the left atrium and right atrium at end-systole
and the transverse dimensions of the left and right ventricle at end-diastole were measured.
Right ventricular function was assessed qualitatively (on a scale from 1=normal to 4=
Table 2
Decrease in SatO2-rest and decrease in NYHA class between baseline and ﬁnal visit.
Total population,
N=77
No event group,
N=37
Event group,
N=34
P-value
Absolute decrease
in SatO2-rest (%)
2.1±6.1 0.0±59 5.5±4.7 b0.0001
Rate of decrease
in SatO2-rest
(%/year)⁎
0.5 (−0.7; 2.0) 0.0 (−1.1; 1.0) 2.2 (0.4; 7.6) b0.0001
Increase in NYHA
class, n (%)
15 (21) 5 (11) 10 (37) 0.010
SatO2-rest: resting oxygen saturation; NYHA: New York Heart Association.
⁎ Median with interquartile range, between-group comparison with Mann–Whitney
U test.
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plane systolic excursion (TAPSE) fromM-mode recordings. A TAPSEb16 mmwas consid-
ered as a decreased right ventricular function [9]. Systolic pulmonary artery pressure was
obtained fromDoppler recording using themodiﬁed Bernoulli equation (4 times tricuspid
regurgitation peak systolic velocity squared).
2.3. Data collection during follow-up
Patient follow-up consisted of consecutive evaluations at a regular time basis of at
least 6 months. At every visit, clinical and biochemical characteristics were evaluated.
Transthoracic echocardiography was repeated every 6 or 12 months. The most recent
evaluation or the evaluation before the occurrence of an end-point (death, hospitalisation
due to right heart failure or transplantation) was considered the ﬁnal visit.
2.4. Composite endpoint
In the registry, information on death, transplantation and the need for hospitalisation
was included. The composite endpoint was deﬁned as all-causemortality, transplantation
or hospitalisation due to right heart failure. Hospitalizations for the initiation or escalation
of disease targeting therapy were excluded.
2.5. Statistical analysis
Data were analysed using SPSS® for Windows (version 19, SPSS, Chicago). The
Kolmogorov–Smirnov test was used to test normality. Descriptive data for continuous
variables are presented as means±SD or as medians with ranges when appropriate.
Descriptive data for discrete variables are presented as frequencies or percentages.
In a ﬁrst step, changes in variables were evaluated using a paired-t test for continuous
variables or aMcNemar test for proportions,with Bonferroni correction formultiple testing.
In a second step, subgroups (event vs no-event group) were compared using an
independent student t-test or a Mann–Whitney U test for continuous variables or a
Chi-square test for proportions. The rate of decrease in SatO2-rest was calculated as
the difference between the baseline value and the value at the ﬁnal visit, divided by
the time interval in years. In order to obtain a clinical meaningful variable, clinical deteriora-
tion was deﬁned as a rate of decrease in SatO2-rest ≥75th percentile, an increase in NYHA
class or a decrease in 6 minute walk to a value below 300 m.
In a third step, uni- and multivariate Cox-regression analysis was performed with
the composite endpoint as a dependent variable. Patients were censored after the ﬁrst
event. Clinical deterioration was corrected for baseline variables: “age at inclusion, iron
deﬁciency, right ventricular function and disease targeting therapy”. Disease targeting
therapywas included in the Cox regressionmodel as a timedependent variable in order to
account for therapy started during follow-up. The level of signiﬁcance for themultivariate
model was set at 0.05.
In the last step, we evaluated the additional value of a deterioration in exercise capacity
or SatO2-rest for risk stratiﬁcation. Risk factors at baseline included NYHA≥3, right ventric-
ular dysfunction (TAPSEb16 mm) and iron deﬁciency. Deteriorationwas deﬁned as patients
with an increase in NYHA or a 6 minute walk distance b300 m or a decrease in SatO2-rest
≥75th percentile. Kaplan–Meier analysis and the log-rank test were performed.
3. Results
3.1. Patient characteristics
Seventy-seven Eisenmenger patients (mean age 36±14 years;
30% male) were included, 10 with atrial septal defect, 23 with atrio-
ventricular septal defect, 22 with ventricular septal defect, 6 with a
patent ductus arteriosus and 16 with other underlying heart defects.
Patient characteristics at baseline and at theﬁnal visit for the entire cohort
are summarized in Table 1.
Although patients with an event during follow-up were more inten-
sively treated at baseline andweremore likely to receive add-on therapy
during follow-up, a signiﬁcant increase in NYHA class (Pb0.0001), a
decrease in 6 minute walk distance (P=0.006) and a decrease in
SatO2-rest (Pb0.0001) were observed in the event group. There was
no signiﬁcant change in right ventricular function (P=0.078) or renal
function (P=0.429).
Between-group comparison indicated that patients in the event group
had a higher NYHA class at baseline and at the ﬁnal visit when compared
to patients in the no-event group. Six-minute walk distance at the ﬁnal
visit was signiﬁcantly lower in the event group when compared to the
no-event group. Patients in the event group were more likely to be iron
deﬁcient. Although SatO2-rest was not different at baseline, patient in
the event group had a lower SatO2-rest at the ﬁnal visit. Despite the
lower SatO2-rest, these patients had lower hemoglobin, meancorpuscular volume and mean corpuscular hemoglobin values
than patients in the no-event group. Right ventricular function at
baseline and at the ﬁnal visit was lower in the event than in the
no-event group (Table 1).
The absolute decrease and the rate of decrease in SatO2-rest were
higher in the event than in the no-event group. Moreover, a greater
proportion of patients increased NYHA class during follow-up in the
event-group (Table 2). Fig. 1 shows a progressive decrease in SatO2-rest
in the event-group whereas it remains stable in the non-event group.
3.2. Variables related with outcome in univariate analysis
During a mean follow-up period of 4.0±2.1 years, 27 (35%) events
occurred. Thirteen (17%) patients died, 2 (3%) underwent transplanta-
tion and 21 (27%)were hospitalized during follow-up. Variables related
with adverse outcome in univariate analysis are summarized in Table 3.
3.3. Variables related with outcome inmultivariate Cox regression analysis
After adjustment for age, the need for disease targeting therapy and
iron deﬁciency, multivariate Cox regression analysis indicated that
clinical deterioration was independently related with adverse out-
come (HR 4.26; 95%CI 1.62–11.14; P=0.003)
In a subgroup of patients (without complex congenital heart disease),
after adjustment for age, the need for disease targeting therapy and right
ventricular function, multivariate Cox regression analysis indicated that
clinical deterioration was independently related with adverse outcome
(HR 4.67; 95%CI 1.60–13.68; P=0.005) (Table 4).
3.4. Additional value of deterioration in exercise capacity or SatO2-rest in
the evaluation of Eisenmenger patients
Based on differences in baseline parameters between the event and
no-event group, 3 risk factors were identiﬁed: NYHA class ≥3, right
ventricular dysfunction and iron deﬁciency. An increasing number of
risk factors at baseline was related with a lower event-free survival
when compared to patients without risk factors (Fig. 2). Clinical deteri-
oration (determined from signiﬁcant changes during follow-up in the
event-group: increase from NYHA≤2 to≥3 or a 6 minute walk distance
to a value b300 m or a decrease in SatO2-rest≥2% per year) was added.
Kaplan–Meier analysis indicated a stepwise increase in the event rate
with additional risk factors present. Moreover, there were no events in
the group of patients without risk factors (Fig. 3). In order to evaluate
the impact of the model on all-cause mortality, Fig. 4 shows that an in-
creasing number of risk factors was also related with higher mortality.
4. Discussion
This prospective study indicated that a deterioration in exercise
capacity and SatO2-rest was related with adverse outcome in
Eisenmenger patients, irrespective of treatment status or baseline
Fig. 1. In the event-group there is a progressive decrease in SatO2-rest, whereas SatO2-rest remains stable in the no-event group (plot indicates group mean with mean conﬁdence interval).
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provided more accurate information on which patients were at risk to
develop an event during follow-up, as compared to baseline parameters
alone.
4.1. Changes in variables related with adverse outcome
Several clinical variables have been related with poor prognosis in
Eisenmenger patients, including higher NYHA class, renal dysfunction,
signs of right heart failure, a history of arrhythmias, iron depletion and
elevated brain natriuretic peptides [4–10,18,19]. However, little is
known about the relationship of changes in clinical variables with out-
come in Eisenmenger patients. Our results indicated that an increase
in NYHA during follow-up is related with adverse outcome, even after
correction for baseline variables, including disease targeting therapy.
Although initiation of disease targeting therapy improves the propor-
tion of patients in NYHA class 1 or 2, changes in NYHA have only been
related with outcome in patients with idiopathic pulmonary arterial
hypertension [20]. Therefore, our results conﬁrm the current practice
guidelines that an increase in NYHA warrants the need for startingTable 3
Univariate Cox regression analysis of variables related with adverse outcome deﬁned
as a composite endpoint of all-cause mortality, hospitalization due to right heart failure
or transplantation.
Variable Hazard ratio (95%CI) P-value
Age (years) 1.03 (1.00–1.06) 0.033
Male gender 0.750 (0.30–1.88) 0.540
Down syndrome 2.08 (0.92–4.72) 0.080
Complex defect 1.53 (0.97–2.42) 0.067
DTT 1.58 (1.11–2.24) 0.010
NYHA≥3 2.42 (1.11–5.28) 0.027
6MWD b300 m 2.53 (0.98–6.49) 0.054
SatO2-rest (%) 1.01 (0.96–1.06) 0.768
MCV (fL) 0.93 (0.88–0.97) 0.002
MCH (pg) 0.81 (0.73–0.90) b0.0001
Iron deﬁciency 3.99 (1.66–9.60) 0.002
LA apical (mm) 1.06 (1.02–1.11) 0.004
RA apical (mm) 1.09 (1.05–1.14) b0.0001
RV function 2.59 (1.60–4.21) b0.0001
TAPSE (mm) 0.88 (0.80–0.98) 0.020
Clinical deterioration 1.60 (1.06–2.41) 0.002
DTT: Disease targeting therapy; 6MWD: 6 minute walk distance; NYHA: New York Heart
Association class; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin;
LA: left atrium; RA: right atrium; RV: right ventricular; TAPSE: tricuspid plane annulus
systolic excursion. Clinical deteriorationdeﬁned as increase inNYHA class, rate of decrease
in SatO2-rest ≥2% per year.or escalation of disease targeting therapy in these patients. Although
not available in all patients, a decrease in 6 minute walk distance to a
value b300 m was related with worse outcome. Six minute walk
distance has been related with worse outcome [10], but a change in
6 minute walk distance was not yet been related with outcome. Until
now, SatO2-rest in Eisenmenger patients was not unequivocally related
with outcome [10]. Interestingly, Diller et al. recently showed that initi-
ation or escalation of disease targeting therapy in Eisenmenger patients
improved oxygen saturation at peak exercise, providing a possible
explanation for the improvement in 6 minute walk distance with
disease targeting therapy [13,21]. Our study indicated that a decrease
in SatO2-rest is also related with adverse outcome even after adjust-
ment for baseline variables and concomitant disease targeting therapy.
Although a decrease in SatO2-rest can be explained by many factors,
including changes in systemic vascular resistance and ﬁlling pressures,
progressive pulmonary vascular disease should be considered in these
patients [13]. Right ventricular dysfunction has important prognostic
signiﬁcance in patientswith pulmonary arterial hypertension, including
Eisenmenger patients [9,22] and there have been reports suggesting
that disease targeting therapy may improve right ventricular function
[23]. Although right ventricular function was worse in patients with
events, there was no apparent change in TAPSE during follow-up.Table 4
Multivariate Cox regression analysis of variables related with adverse outcome deﬁned
as a composite endpoint of all-cause mortality, hospitalization due to right heart failure
or transplantation. (A) Clinical deterioration was corrected for age, the need for disease
targeting therapy and iron deﬁciency. (B) Clinical deterioration was corrected for
age, the need for disease targeting therapy and right ventricular function in a subgroup
excluding patients with complex congenital heart defect.
Variable Hazard ratio (95%CI) P-value
A.
Age (years) 1.01 (0.98–1.04) 0.653
DTT 1.39 (0.93–2.07) 0.107
Iron deﬁciency 2.93 (1.05–8.21) 0.041
Clinical deterioration 4.25 (1.62–11.14) 0.003
B.
Age (years) 1.02 (0.99–1.04) 0.219
DTT 1.42 (1.00–2.01) 0.051
TAPSEb16 mm 0.86 (0.20–3.66) 0.864
Clinical deterioration 4.67 (1.60–13.68) 0.005
DTT: Disease targeting therapy. Clinical deterioration deﬁned as increase in NYHA class,
rate of decrease in SatO2-rest ≥2% per year.
Fig. 2. Kaplan–Meier plot indicating event-free survival according to the number of risk factors present at baseline. Risk factors included the presence of NYHA≥3, right ventricular
dysfunction deﬁned as TAPSEb16 mm and iron deﬁciency.
Fig. 3. Kaplan–Meier plot indicating event-free survival according to the number of risk factors evaluated at baseline and during follow-up. In addition to baseline risk factors
(NYHA≥3, iron deﬁciency and right ventricular dysfunction), clinical deterioration (deﬁned as an increase in NYHA class from ≤2 to ≥3, a decrease in 6 minute walk distance
to b300 m or a rate of decrease in SatO2-rest ≥2% per year) was considered.
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Fig. 4. Kaplan–Meier plot indicating event-free survival according to the number of risk factors evaluated at baseline and during follow-up.
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capacity or SatO2-rest in predicting adverse outcome of ES patients
Several studies have indicated a symptomatic improvement in
Eisenmenger patientswith bosentan [24–27]. The Bosentan Randomized
Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) and the 6 month
open-label extension study indicated a beneﬁcial effect of bosentan in
NYHA 3 Eisenmenger patients [13,28]. More recently, studies including
NYHA 2 and 3 Eisenmenger patients indicated that phosphodiesterase-
inhibitorsmay also improve exercise capacity [29–32]. The only study in-
cluding exclusively mildly symptomatic (NYHA 2) patients with pulmo-
nary arterial hypertension (but which only included a subgroup of
patientswith pulmonary arterial hypertension associatedwith congenital
heart disease(17%)) suggested a beneﬁcial effect of bosentan [33].
When evaluating exercise capacity using cardiopulmonary exer-
cise testing and considering a strict deﬁnition of NYHA class, virtually
all Eisenmenger patients should be classiﬁed in NYHA class 2 [34–36].
However, Eisenmenger patients often report a better than expected
perceived health and it has been shown that there is a lack of consis-
tency in classiﬁcation between clinicians [37,38]. Nevertheless, NYHA
remains a powerful prognostic tool even in Eisenmenger patients as it is
the often the only parameter evaluating exercise capacity [37]. Moreover,
assessing changes in variablesmaybe important predictors of outcome as
they speciﬁcally confer to deterioration of a parameter in a single patient.
In this study, we consecutively evaluated the ability to predict an
event using baseline parameters only and baseline parameters in combi-
nation with parameters reﬂecting deterioration of patients. Baseline risk
factors have beendescribed before [9] and appear complementarywith a
higher risk in patients with more risk factors present. Importantly, we
were able to demonstrate that risk stratiﬁcation combining baseline
and follow-up variables is superior to that based on baseline variables
alone, with sensitivity and speciﬁcity improving the more risk factors
are present. The current study may help in clinical decision making,
especially guiding the decision to start or escalate disease targeting
therapy. The use of NYHA≥3 or increase in NYHA during follow-up tostart or escalate disease targeting therapy is a close reﬂection of current
clinical practice and is supported by the current evidence [15]. If pa-
tients fall below 300 m in their 6 minute walk distance their prognosis
appears impaired, suggesting the need to intensify treatment. Finally, as
disease targeting therapy is able to increase oxygen saturation [21],
a patient with a deterioration in SatO2-rest may beneﬁt from the
initiation or escalation of disease targeting therapy.5. Limitations
First, due to the nature of the condition, the number of patients
was relatively low. However, the data was sufﬁcient to perform the
appropriate statistics. Second, not all patients had information on
iron status, TAPSE or 6 minute walk distance at baseline and follow-up,
which would have provided additional prognostic information. Third,
neither laboratory nor echocardiographic data were analyzed in a core
laboratory, whichmay have inﬂuenced standardisation of results. Fourth,
values of SatO2-rest were only obtained at baseline and at the ﬁnal visit.
Therefore, one cannot be sure that SatO2-rest decreases linearly. Fifth,
data for the study was obtained through the Belgian Adult Congenital
Heart Disease registry. As only patients who gave written informed
consent were included in the study, a selection bias may be present.
Finally, data on BNP-values or NT-proBNP values were not available in
the registry.6. Conclusions
A deterioration in exercise capacity and SatO2-rest is related with
adverse outcome in Eisenmenger patients. Moreover, the deterioration
in exercise capacity and SatO2-rest ≥2% per year provided additional
information on which patients would develop an event during follow-
up and therefore may beneﬁt from initiation or escalation of disease
targeting therapy.
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